RedHill Biopharma shares are trading higher after the company announced a new publication showed data demonstrating that triple antimicrobial therapy with RHB-104 plus standard of care, targeting Mycobacterium avium subspecies paratuberculosis, is 64% more effective than SoC alone in Crohn's disease.
Portfolio Pulse from Benzinga Newsdesk
RedHill Biopharma shares are trading higher after the company announced a new publication showing that triple antimicrobial therapy with RHB-104 plus standard of care is 64% more effective than standard of care alone in treating Crohn's disease.
August 01, 2024 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RedHill Biopharma shares are trading higher following the announcement of new data showing that their RHB-104 therapy is significantly more effective in treating Crohn's disease compared to standard care alone.
The announcement of the new data demonstrating the effectiveness of RHB-104 in treating Crohn's disease is a significant positive development for RedHill Biopharma. This could lead to increased investor confidence and a rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100